# A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

> **NCT07115329** · PHASE2 · RECRUITING · sponsor: **Syndeio Biosciences, Inc** · enrollment: 164 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Zelquistinel

## Key facts

- **NCT ID:** NCT07115329
- **Lead sponsor:** Syndeio Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-06
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115329, "A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07115329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*